Accumulating data indicate that restoration of AR signaling is critical for disease progression in these patients, as AR overexpression, especially due to AR genomic amplification, has been frequently observed and proven to be a principal driver of prostate cancer progression, both in clinical CRPC patients and in preclinical prostate cancer cell models [12–16]. This evidence concerns the gene AR and prostate carcinoma.